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Introduction 
   Since in the Alzheimer disease (AD) the neurotoxicity was associated to the preliminary acquisition by amyloid 
peptides (Aβ) of a beta sheet conformation [1,2] which in turn leads to different forms of toxic aggregates, the 
inhibition of the aggregation could be a realistic therapy for this pathology. β-sheet breakers (BSB) are short synthetic 
peptides able to interact with Aβ without becoming part of the β-sheet structure, destabilizing the Aβ conformer, thus 
precluding reciprocal stacking. In this study a series of analogues of the peptide Ac-LPFFD-NH2 (iAβ5p), reported 
by Soto as a BSB model [3-5], were synthesized and tested as fibrillogenesis inhibitors. 
 
Results       
   Firstly we found that the substitution of the N-acetyl group of iAβ5p with an N,N-dimethyl-taurine (DM-Tau) gave a 
sulphonamide junction-containing analogue, which showed a higher BSB activity on Aβ1-40 and an increased 
resistance to proteolysis, compared to iAβ5p itself [6]. On this basis, we synthesized and tested the activity of three new 
analogues in which a taurine, an N,N-dimethyl-β-alanine and a β-alanine substituted the DM-Tau into the original 
sequence of the previous esapeptide. These new compounds demonstrated an in vivo protective effect of the taurine-
containing analogues and confirmed their capability to hinder fibrillogenesis in vitro [7]. 
   Successively, we  pay our attention on the synthesis of new peptides containing the same N-terminal modifications 
along with changes at their central region by substituting one or both phenylanines of iAβ5p and of its DM-Tau-
containing derivative with an α,β-dehydro-phenylalanine (ΔPhe).  
  
Conclusions 
   These results underlined the usefulness of the modification at the N-terminal position of the peptide derivatives related 
to iAβ5p and pointed a cytoprotective activity of the sulfonamide junction against the amyloid toxicity in vivo. Studies 
on the ΔPhe-containing peptides are now in progress. 
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Introduction 
Due to its involvement in Alzheimer’s disease, the understanding of the mechanisms underlying the aggregation of the 
amyloid β-peptide (Aβ) ) is of extreme importance. In fact, depending on external parameters such as pH, temperature, 
concentration, ionic strength, stirring, etc., Aβ peptide may undergo a variety of different aggregation processes, leading to 
aggregates of different size, morphology and toxicity level1. These processes have been characterized under various 
conditions. Moreover, possible mechanisms of inhibition of the aggregation, for the Aβ peptide as well as for other 
proteins, have been studied  by using a-casein as a stabilizing agent. 
 
Methods 
The experimental approach is based on the application of different complementary techniques. Light scattering, both static 
and dynamic, is used to gain information on the size and the structure of particles in solution. The nature and the properties 
of the aggregates are investigated by means of circular dichroism, Atomic Force Microscopy, and fluorescence on external 
dyes such as Thioflavin T and ANS.  
 
Results 
At low pH, Aβ peptide undergoes a colloidal coagulation, leading to very large aggregates, composed of smaller amyloid 
structures2. At physiological pH, the nature of the obtained aggregates (amyloid or amorphous) strongly depends on the 
ionic strength of the solvent and on stirring3. 
The milk protein α-casein was found to be a potent inhibitor of the amyloid aggregation of the Aβ peptide, acting by means 
of monomers and/or small oligomers sequestration4. The study of the effects of α-casein on the amyloid aggregation on a 
larger protein (Concanavalin A), revealed another possible mechanism of action of α-casein5, which can have analogies 
with the mechanisms of the inhibition observed in the case of Aβ peptide with β-breakers. 
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Introduction   
A general characteristic of aggregation is the multiple interaction and cross-feedback among distinct mechanisms 
occurring at different hierarchical levels. The comprehension of the different species interconversion during aggregation 
is very important since emerging evidences indicate intermediate oligomeric aggregates as primary toxic species. In this 
context, Aβ amyloid peptide provides a challenging model for studying aggregation phenomena both for the complexity 
of its association process and for the direct implications in Alzheimer’s Disease. Aggregates growth conditions strongly 
affect the final morphology, the fibrillar molecular structure as well as the aggregation pathway which is characterized 
by the occurrence of multiple transient species.    
 
Methods  
 The fluorescent dye Thioflavin T (ThT) is widely used to detect amyloid deposits and it is often used in situ to study 
aggregation kinetics, under the hypothesis that its presence does not affect the aggregation processes under study. Here 
we present an experimental study on Aβ(1-40) peptide fibrillation kinetics at pH 7.4. In the observed conditions, Aβ(1-
40) undergoes aggregation only if Thioflavin T is present in solution. This phenomenon was analyzed as a function of 
temperature, ThT and peptide concentrations in order to explore the underlying fibrillation mechanism. Light scattering, 
ThT fluorescence emission, two photon excitation fluorescence microscopy, were used in a kinetic fashion to highlight 
different sides and critical phases of the aggregation pathway. Circular Dichroism and FTIR measurements are used to 
characterize secondary structure of the aggregates.    
 
Results  
 The selected approach gives detailed information on the time evolution of Aβ(1-40) fibrillation process highlighting 
structural changes at molecular level, different aggregate species growth and their morphologies. Our data show that 
Aβ(1-40) fibrillation process occurs only in the presence of ThT and that the observed aggregation involves at least 
three different aggregation mechanisms acting in competition. In the first step, small oligomers, which bind ThT, are 
formed via non nucleated polymerization mechanism and represent an activated state for following fibrils growth. This 
process appear to be a rate limiting step for two distinct fibril nucleation mechanisms probably affected by an high 
degree of spatial heterogeneity.    
 
Conclusions   
We demonstrated that in the selected experimental conditions ThT triggers the Aβ(1−40) fibrillation process (D’Amico 
et. al 2012). Sterical and chemical properties of ThT molecule may modulate the peptide conformation, with similar 
mechanisms to the ones that usually drive the binding of this dye to already formed amyloids. So, the presence of ThT 
in solution may change the thermodynamic equilibrium trapping specificmore ordered conformations prone to 
supramolecular assembly.    
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Quantitative Structure–Activity Relationships of peptides: basic notions. 
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--------- 
 
Introduction 
Since the birth of modern chemistry, investigators have always been eager to understand the structural and physical 
chemical basis of the biological activity of chemicals, one of the main aims being their “domestication”. A brilliant 
illustration of how the concepts and practice of Structure-Activity Relationships (SAR) had a strong acceleration in 
toxicology in the mid 1980’s is provided by E.J. Ariens 1. One approach is the qualitative one, that takes into account 
the significance of particular groups in the molecule for particular aspects, part processes, in the biological action. 
Examples are groups described as pharmacophores or toxicophores or Structural Alerts (SA). This can be called a 
coarse-grain approach. The other approach (fine-tuned) is the formalized Quantitative Structure-Activity Relationships 
(QSAR) approach.  
     The foundation of QSAR came almost fifty years ago, when Corwin Hansch found the way to bring together two 
areas of science which had seemed far apart for many years: physical organic chemistry, and the study of Chemical ↔ 
Life Interaction 2,3. This model worked for an enormous number of biological problems, and its success is demonstrated 
clearly by its widespread diffusion. In the years subsequent to the 1960's, the need to solve new problems, together with 
the contributions of many other investigators, generated hundreds of variations of the Hansch approach, as well as 
approaches that are formally completely new. For example, new descriptors generated through direct mathematical 
modeling of chemical structures were introduced 4,5,6 7,8, and the range of mathematical models used to link chemistry 
and biology has expanded accordingly 9,10,11,12,13,14.  
 
Conclusions 
The QSAR science still maintains a fundamental unity, founded on the systematic use of mathematical models and on 
the multivariate point of view.  At present, the QSAR science is one of the basic tools of modern drug and pesticide 
design, and has an increasing role in environmental sciences 15,16,17,18,19,20,21. A great aspect of the QSARs –especially 
when applied within individual chemical classes- is that they point to the chemical determinants of the biological 
activity of the compounds; thus they can contribute to the rationalization of the biological activity mechanisms 3.     
Its nature of general methodology permits the application and extension to all types of biological activity, including 
peptides and proteins 22,23.   
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Multi Agent System (MAS) based simulation of β –breakers’ function. 
Alfredo Colosimo 
”Sapienza” University of Rome - Dept. SAIMLAL 
--------- 
Introduction 
Mathematical models (MMs) are abstract models using mathematics to describe and possibly predict the behaviour of physical and 
biological systems. By appropriate assumptions MMs reveal precious to gain insight into the dynamics of systems whose 
differential equations are not amenable to analytical solutions.  Models based on Multi Agent Systems (MASs) consider  clusters 
of computational units (agents) interacting among each other and with the environment on the basis of simple rules.  The time-
dependent  changes in MAS features can be taken as a reliable simulation of the complex, phenomena involving social, economic, 
and even molecular events.   
Methods 
Any MAS simulator ultimately derives from the seminal work of  John Conway on cellular automata [1], namely autonomous, 
self-organizing and self-steering computational elements. In the present contribution we took advantage, in the family of the 
Artificial Intelligence ‘Logo’ languages, of the NETLOGO [2] programming environment endowed – among a  number of 
desirable features - with a friendly graphical user interface. We  used NETLOGO  to simulate: a) the action of β-breakers on the β 
-sheet structure of single fibrils at a microscopic, molecular  level, and b)  the emergence of cooperative effects in switching from 
one conformation to another at a macroscopic, population level. 
Results 
A crucial role in fibrillogenesis was assigned  to the II structure of palindromic sequences in prion peptides [3] where by far the β-sheet prevails. 
Hence, such palindromic sequences should be included in any model accounting for the properties of β-breakers.  Fig. 1  shows how MAS 
simulators reproduce the effect of the  repulsive force taking place between single palindromic sequences and β-
breakers.   
Even the massive accumulation of insoluble amyloid aggregates can be associated to the switching from the coil  to 
the β-sheet conformation at the level of single fibrils, and simulated accordingly. In the bidimensional representation 
of Fig. 2 the two conformations are represented  by the black or white color assigned to nodes in a network where 
distances (links) between each pair of nodes have been omitted for the sake of clarity. For each single node, switching 
from one to the other state depends on the state of its neighbours, and this is shown to produce, at the global 
population level, different final states from the same initial configuration. 
Figure1.  Simulating the effect of a β-breaker on the II structure of  the VAAAAAAAAV decapeptide. 
In the top and bottom panels the II structure of the decapeptides is reported before (a, b) and after (a’, b’)  running 100 
iteration steps, respectively.  In each step the initial relative position of decapeptide and β-breaker residues (c, c’) is 
modified by an algorithm trying to get the residues as far as possible from each other, subject to the limitation imposed by the links (peptide 
bonds). Notice that in both panels changes in the a, a’ decapeptides are minimized by the bigger distance from the β-breakers (c, c’). 
 
 Figure 2. Simulating the β−sheet ↔ coil cooperative switch in a fibrils 
population. 
The left panel shows the randomly distributed conformations  (black or 
white color) within a population of amyloid fibrils. In the representation 
of the system as a dynamic network, at each time step the conformation 
of each node (fibril) is made the same as that of the first neighbours.   
The abundance of the two conformational states is reported in the bottom 
section of each panel. For the given initial configuration (panel A), the 
initial prevalence (60%) of one state does not originate the same final 
state after 200 time steps (panel B, C), pointing to the randomic nature of 
the aggregation process.  
Conclusions 
Although the structural modifications induced by β-breakers on amyloid fibrils can be successfully reproduced by standard 
molecular dynamics [4], a MAS based simulation study is made worth of pursuing by the following considerations:  i) The 
implementation even of sophisticated mechanistic models is relatively straightforward. Thus, the influence of a large number of 
variables on the very complex amyloid aggregation process can be qualitatively explored in a short time. ii) For a given model, the 
statistical significance of the simulations can be increased at will by up-scaling the size of the agents’ population.  iii) The highly 
flexible time and space parceling in the iteration steps, allows to explore a wide range of time windows and spatial arrangements.   
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Introduction 
The basic assumption of medicinal chemistry is that the most similar two chemicals are, the most similar their biological 
activity is supposed to be (1). Even if there exist many exceptions to this rule we can consider the relation between 
chemical and biological activity similarities a reliable and useful work hypothesis as demonstrated by its widespread use in 
applied science (2). Establishing a Quantitative Structure Activity Relation (QSAR) implies a thorough definition of what 
chemical similarity is, that in the case of small organic molecules is approached by the use of multidimensional statistics: 
the considered molecules are the statistical units (rows) of a data set (training set) having as columns (variables) some 
carefully selected chemico-physical descriptors of the considered molecules. These variables correspond to the set of 
‘regressors’ (or X variables) , while one or more Y variable are added as well in order to describe the biological activity of 
the same compounds. The goal is to find a statistically relevant correlation linking X and Y variables that will be in turn 
verified by its ability to predict the biological activity of another independent set of molecules (test set).  The same 
approach can in principle (and as a matter of fact it was) used for peptides and proteins, the basic point to keep in mind is 
the need of a careful consideration of the ‘order’ properties of biological polymers that must be embedded in the data 
representation. Here we will briefly discuss the two main methods to take into consideration this point in protein and/or 
peptide QSAR. 
 
Methods 
There are two basic methods in order to keep the ‘native order’ of polymers alive in a QSAR-like approach a direct and an 
indirect (or holistic) one. The direct method ends up into an Xs (regressors)  matrix having as rows the different peptides 
(proteins) and as columns the relevant chemico-physical descriptors at the corresponding positions along the sequence. The 
following tables depict the essence of this kind of approach: the analyzed sequences are initially represented like this: 
 
Table 1a 
Peptide  Pos.1 Pos.2 Pos.3 Pos.4 Pos.5 Pos.6 Pos.7 
P1 A R A N N D C 
P2 A H I N N W C 
P3 R R A D N D M 
 
The variables correspond to the different locations along the sequence with their corresponding residues, the above matrix is 
then transformed as in Table 1b by the substitution of symbols with corresponding chemico-physical descriptors of the 
corresponding residue. 
Here we will report as descriptor Miyazawa-Jernigan (MJ) (3) hydrophobicity score, but we can in principle add many other 
descriptors by adding new columns (keeping invariant the original peptide order) to the matrix. 
 
Table 1b 
Peptide Pos.1 Pos.2 Pos.3 Pos.4 Pos.5 Pos.6 Pos.7 
P1 1.6 -12.3 1.6 -4.8 -4.8 -9.2 2 
P2 1.6 -3 3.1 -4.8 -4.8 1.9 2 
P3 -12.3 -12.3 1.6 -9.2 -4.8 -9.2 9.36 
 
Before entering the supervised learning phase the original data set is made amenable to a sound modelling phase by the 
ordinary multidimensional statistical methods (4). What is important to note is that the direct (beside the need to have equal 
length sequences that can be circumvented by autocorrelation techniques like in (5)) makes a strong assumption about the 
existence of a ‘specific role’ typical of each position and invariant across the data set. When this is actually the case, this 
approach is extremely powerful given it produces a very detailed information that is immediately operative in terms of 
suggestions for the synthesis of new molecules expected to have a relevant biological activity without the need of any further 
theoretical assumptions.  
When the above constraints are not met and we are facing very different systems (7) in terms of both size and shape, we 
must change our strategy accordingly trying and select some invariant descriptors from protein structure and/or sequence 
that, being relative to the protein molecule as a whole, can be applied to very different systems keeping alive their general 
meaning. There exist plenty of these global descriptors (8,9,10) , relying on the consideration of proteins as  graphs having 
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as nodes the aminoacid residues and as edges the scoring of a  significant interaction between the nodes (11). In the case of 
protein dynamics the interaction between graph nodes is the correlation between the trajectories of the correspondent 
aminoacids. In the case of primary structures the relevant interaction corresponds to a pairwise chemico-physical similarity 
between the residue pairs (11) , in the case of 3D structure their small distance in space (8). In all given protein graphs are 
described by an NxN (with N=number of residues) adjacency matrix whose invariants correspond to the global descriptors.  
Fig.1 reports three different adjacency matrix correspondent to the above three protein views: 
 
 
 
 
The network invariants correspond to different descriptors of the graphs based only on their wiring structure (and thus independent 
on the kind of interaction they are focused on) such as general connectivity, characteristic length (or average shortest path, the 
average length of the shortest path linking the different couples of nodes) and so forth that represent the regressors for predicting 
protein physiological features.  
 
Conclusions 
All in all, we can safely state that the merging between multidimensional statistics and sensible quantitative descriptors of 
proteins at different level of detail can be a very powerful method to approach specific problems like the synthesis of 
efficient beta-breakers peptides in a rational and quantitative way. 
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Looking "inside" breakers and Aβ-peptide interaction: a computational approach  
V. Minicozzi, S. Morante, C. Narcisi 
Department of Physics, University of Rome “Tor Vergata” 
 
We present preliminary results of classical Molecular Dynamics (MD) simulations   performed with the main goal of 
reproducing and thus possibly interpret the salient   features of findings (1) of selected experiments, purposely devised 
for comparing the   anti-aggregating activity of a group of specific beta-sheet-breakers (BSBs) peptides.   The strength 
of our MD approach resides in the possibility provided, at least in   principle, by numerical simulations of blowing up 
even very small portions of the   investigated system and looking at what happens at the atomic level. Four model   
systems have been subjected to MD simulations. They are built by dissolving in water   either the Aβ1-40 alone (from 
now on called abeta   model) or in the presence of 10   copies of the following three BSB peptides: LPFFD, chosen to 
mimic the 17-21   sequence of the Aβ1-40 peptide (lpffd model); taurine-LPFFD, tau-lpffd; and LPFFN,   lpffn. After a 
standard equilibration procedure, a 80 ns NpT MD simulation at 300 K   is started. The starting Aβ1-40 structure is taken 
from PDB (ID: I1YT) while the BSB’s   are all taken in an all-trans configuration. Structural differences among the four   
models are already visible after the equilibration procedure, and they become much   greater at the end of the actual MD 
simulation. In particular, it seems that in the abeta   and lpffn   systems the Aβ1-40 peptide has the tendency of 
conserving longer α -helix   portions (2). Looking at lpffd   model, the Aβ1-40 peptide looks more disordered than in   the 
abeta   one, but another important feature emerges: in the course the MD evolution, β-sheet strands are formed, between 
Aβ1-40  and either one or two BSBs. The same   feature is also visible in the tau-lpffd   model. In the lpffn   case, instead, 
the β-sheet   structure, that appears already after 10 ns MD, is now formed between two breakers   and does not involve 
the Aβ1-40 peptide. What is interesting to note is that the   conserved α-helix Aβ1-40 portion is located in the region that 
happens to be nearest to   the two BSBs that form the β-sheet. In summary, three main preliminary results are   worth 
recalling and retaining for the moment: i) The Aβ   peptide loses most of its α-helix   structure already as it is solvated; 
ii) there seem to be no preferred locations   along the Aβ  peptide for BSB docking; iii) β-sheet structures get formed 
between the Aβ peptide and one BSB or between pairs of LPFFN breakers. For the immediate   future, we are planning 
to add in solution at least a second Aβ peptide, by either   having a system with two Aβ peptides in water free to 
interact, or by starting from an   aggregated two-Aβ-peptide structure with the aim of studying the ability of BSBs of   
"undoing" the aggregate. We would like also to test the effect of adding metals (like   Cu or Zn ions) to the systems 
studied, as they are known to affect Aβ   aggregation   propensity.   
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DNA methylation: a unifying hypothesis on Alzheimer's disease and Down syndrome? 
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Introduction 
Folate metabolism, also referred to as one-carbon metabolism, is required for either DNA synthesis or methylation. 
Methylation of cytosine represents one of the most important epigenetic mechanisms for gene regulation and tipically 
occurs in a CpG dinucleotide context. Promoter hypermethylation is commonly associated with gene silencing and 
promoter demethylation with gene expression. DNA methylation also forms the basis of chromatin structure, and 
participates in chromosome recombination and segregation. Increasing evidence suggests that impairments of gene-specific 
DNA methylation might be involved in the pathogenesis of Alzheimer’s disease (AD) (1). Moreover, virtually all 
individuals with Down syndrome (DS) develop AD by the fourth decade of life, due to the presence of three copies of the 
APP gene that maps to chromosome 21, and it has been suggested that maternal impairments in DNA methylation of 
centromeric regions might favour chromosome 21 malsegregation and predispose the mother to the birth of a child with DS 
(2). We are currently investigating the contribution of genetic polymorphisms of genes involved in folate metabolism and 
DNA methylation reactions to the risk of both AD and DS.  
 
Methods 
We are screening a large cohort of almost 400 AD subjects and 300 healthy matched controls for the presence of common 
polymorphisms of genes involved in folate metabolism in order to correlate them to both AD risk and to circulating levels 
of folate, homocysteine and vitamin B12 levels. Similarly we are screening a cohort of over 100 mothers of DS individuals 
and 100 matched control mothers to evaluate the contribution of folate gene polymorphisms to the maternal risk for having 
a birth with DS, as well as to chromosome damage and malsegregation events. 
 
Results 
We observed significantly increased homocysteine and decreased folate levels in AD patients with respect to controls (3). 
Both MTHFR C677T and MTRR A66G polymorphisms have been associated with increased AD risk and with folate 
and/or vitamin B12 levels in our cohort (3). Promoter polymorphisms of the DNMT3B were not associated with increased 
AD risk (4), and ongoing studies suggest interaction of RFC1 and TYMS polymorphisms with homocysteine levels. 
Concerning DS risk, we observed complex interactions among MTHFR and RFC1, MTHFR and MTR, and MTHFR and 
TYMS polymorphisms with the maternal risk for birth of a child with DS (5,6). Moreover, we observed an increased 
frequency of chromosome damage and malsegregation events in peripheral lymphocytes of MDS with respect to control 
mothers, and an association of MTHFR polymorphisms with the chromosome damage (6,7). More recently, we observed 
association of DNMT3B promoter polymorphisms and maternal risk of birth of a child with DS (8). Meta-analyses of the 
literature are ongoing to further address the contribution of one-carbon metabolism to the maternal risk of birth of a DS 
child. 
 
Conclusions 
The results obtained by us in recent years point to a possible contribution of polymorphisms of gene participating in folate 
metabolism to both circulating levels of folate, homocysteine and vitamin B12, as well as to chromosome damage and 
malsegregation events, thereby contributing to the risk of late-onset AD and to the maternal risk of birth of a child with DS. 
Interestingly, a five-fold increased AD risk was observed in mothers of DS individuals with respect to control women (9), 
and chromosome 21 malsegregation was observed not only in MDS blood cells, but also in blood, buccal cells and brains of 
AD subjects (10-12). In vitro studies showed association between folate deficiency and chromosome 21 aneuploidy (13). 
Further studies are necessary to clarify whether the observed occurrence of chromosome 21 malsegregation in AD cells is 
caused by folate deficiency in AD subjects, likely as a consequence of impaired chromosome 21 methylation, and 
contributes to disease development, or if it is rather a consequence of the disease progression. 
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As the elderly population expands, the prevalence of both Alzheimer’s disease (AD) and Parkinson’s disease (PD) is 
likely to augment. Although the exact cause is not yet finally known, it has been postulated that the behavioural and 
neuronal declines associated with these age-related neurodegenerative disorders are triggered by multi-factorial events 
including neuroinflammation, glutamatergic excitotoxicity, increases in iron and/or depletion of endogenous 
antioxidants (1-3). Accumulating evidence suggests that diet and lifestyle can play an important role in delaying the 
onset or halting the progression of neurodegenerative diseases and improving cognitive function (4). With regards to 
diet, flavonoids have been associated with a reduced risk of developing dementia, an improved cognitive performance 
in normal ageing and an improved cognitive evolution (5-6). However, recent evidence is suggestive that carrier of the 
APOε4 genotype may influence the beneficial effect of flavonoids in relation to dementia and AD (7-8).While many of 
the mechanisms underpinning their beneficial effects remains to be elucidated, it has become clear that they in part 
involve decreases in oxidative/inflammatory stress signaling, increases in protective signaling, and may also involve 
hormetic effects to protect neurons against oxidative and inflammatory stressors. Nethertheless, the therapeutic and 
pharmacological potential of these natural compounds, still remains to be translated in humans in clinical conditions. 
The challenge ahead therefore, is to proceed cautiously until rigorous randomized controlled clinical trials have been 
undertaken to determine empirically whether flavonoids and/or their metabolites have efficacy in individuals affected 
by dementia and other neurodegenerative conditions.  
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Introduction 
The greatest risk factor for Late Onset Alzheimer’s Disease (LOAD) is aging, which is influenced by physiological and 
environmental stimuli. Epigenetic modifications can mediate environmental insults that a person encounters during his life. 
Therefore, epigenetic mechanisms can be considered as a link between environment and its effect on the genome. 
Advances in epigenetic research stressed the involvement of epigenetics in different neurodegenerative diseases, including 
LOAD, the most representative among neurodegenerative diseases. The role of B vitamins and high homocysteine (HCY) 
levels in the onset and progress of LOAD is a controversial topic. Although low B vitamins and high HCY levels were, at 
different degrees, associated with the disease, much work is still necessary to clarify the causal or consequential 
relationship and the underlying molecular mechanisms of this association. 
 
Methods 
In the last years, our laboratory was aimed at studying the role of DNA methylation in AD; to this scope, we analyzed 
methylation of genes associated to the disease in a murine AD model. TgCRND8 mice (carrying a double Indiana/Swedish 
mutated APP transgene) were grown either with control or vitamin B deficient diet, with or without oral supplementation of 
S-adenosylmethionine 400 mg/day. We measured: i) methylation metabolites by HPLC; ii) activity of DNA 
methylases/demethylases; iii) PSEN1 promoter methylation; iv) PSEN1 and BACE expression by Real-Time PCR and 
western blotting; v) amyloid deposition by ELISA tests and immunohistochemistry; vi) cognitive status by water maze. 
 
Results 
We found that PSEN1 gene, involved in amyloidogenesis, is regulated by methylation in hyperhomocysteinemic mice (a 
condition exacerbating AD-like features) through the inhibition of DNA methylases and promotion of DNA demethylation. 
S-adenosylmethionine is able to revert (or prevent) the observed exacerbation of Alzheimer-like features induced by B 
vitamin deficiency in TgCRND8 mice: SAM/SAH ratio decrease, DNA methylation unbalance, PSEN1 promoter 
hypomethylation, PSEN1 and BACE over-expression, amyloid processing and deposition, cognitive impairment. 
 
Conclusions 
Our results demonstrate the existence of specific mechanisms by which epigenetics, in particular DNA methylation, affects 
the progress of neurodegeneration. These findings confirm and extend our previous observation on the role of one-carbon 
metabolism and of methylation reactions in particular, and highlight the molecular mechanism connecting this metabolism 
with AD onset and progression. Possible intervention on one-carbon metabolism, and the use of SAM in particular, for the 
treatment of AD finds an evident rationale on the basis of these results. Since the magnitude of increased/decreased 
amyloid deposition is apparently greater than if simply due to the PSEN1 regulation, we hypothesize than other regulation 
(e.g. the effect of methylation on amyloid aggregation) could be involved. 
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Department of Biochemical Sciences, Sapienza University, Roma, Italy 
 
Introduction 
Neurodegenerative disorders, in particular Alzheimer's disease (AD), are characterized by severe oxidative stress. The major 
cause of free radicals overproduction in AD seems to be related to the overproduction of Amyloid beta (Aβ), which could 
function as a pro-oxidant generating oxygen free radicals via a direct or an indirect mechanism: in the direct one, Aβ binds to 
transition metals ions, acquiring an oxidase activity leading to hydrogen peroxide production, whereas in the indirect 
mechanism neurons or microglia stimulated by Aβ produce oxygen free radicals by activation of NADPH oxidase. 
Free radical injury may be responsible for neuronal loss by inducing DNA damage that in turn activates poly(ADP-
ribose)polymerase enzyme (PARP-1) which catalyzes the covalent addition of the ADP-ribose moiety of NAD+ and the 
subsequent elongation of the polymer mainly to nuclear proteins. A causal relationship between PARP and AD is demonstrated 
by the finding that nuclear proteins are extensively poly(ADP-ribosylated) in the hippocampus of AD affected individuals and 
that the NonAmyloid-beta Component (NAC) of senile plaques activates PARP. 
In the present study we focused on the comprehension of the molecular mechanisms that lead to PARP-1 activation by Aβ and 
to the downstream ways activated by PARP-1.  
 
Methods 
Our experiments were performed both in a cellular model (i.e. SH-SY5Y neuroblastoma derived cells) treated with the Aβ25-35 
fragment, kindly provided by Dr. C. Giordano (CNR centre of Biomolecular Chemistry, Sapienza University), and in an animal 
model of AD (i.e. in TgCRND8 transgenic mice, an early onset model of the disease) kindly provided by Prof. S. Scarpa and Dr. 
A. Fuso (Dept. of Surgery P. Valdoni, Sapienza University). 
 
Results 
Our data show that challenge of SH-SY5Y cells with Aβ25-35 significantly increased PARP-1 activity following ROS generation 
and DNA damage. We also evaluated the capability of betasheet breaker peptides (BSBPs) to counteract cellular responses to 
Aβ25-35-induced damage. Our results demonstrate that BSBPs containing a taurine moiety at the N-terminal were particularly 
efficient in inhibiting PARP-1 activation and in counteracting Aβ25-35-induced cell toxicity.  
Aβ25-35 also activated NFkB via PARP-1, and induced a significant increase in p53 protein levels and a parallel decrease of the 
anti-apoptotic Bcl-2 protein, both of which were reversed by cell pretreatment with MC2050, a new PARP-1 inhibitor.  
In vivo experiments confirmed an involvement of PARP-1 in neurodegeneration. Indeed, PARP-1 activity in brains specimens 
of TgCRND8 transgenic mice was found to be significantly increased in the hippocampus and the same trend observed for p53 
and Bcl-2 in treated cells was confirmed in this brain area. 
 
Conclusions 
The overall data suggest that PARP-1 has a prominent role in the molecular mechanisms induced by Aβ that lead to cell death 
and neurodegeneration, through activation of NF-kB signalling and the modulation of p53 and Bcl-2. Our data also support the 
evidence that BSBPs or PARP-1 inhibitors may represent attractive therapeutic agents to counteract neurodegeneration in AD. 
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Introduction 
One of the histopathological hallmarks of Alzheimer’s disease (AD) is the intraneuronal neurofibrillary tangles that are 
composed of abnormally hyperphosphorylated tau protein. Generally, the level of tau phosphorylation is regulated by the 
equilibrium between the activities of its protein kinases and phosphatases. Although several protein kinases are known to 
act on tau, glycogen synthase kinase 3β (GSK3β) is the major kinase that phosphorylates tau in the brain. Recent studies 
show that overexpression of active Gsk3b results in AD (1, 2). The major phosphatase that dephosphorylates tau is protein 
phosphatase 2A (PP2A) (3). Different groups showed that the highly conserved carboxyl-terminal sequence of PP2A C 
subunit is the site of a reversible methyl esterification reaction that control the formation of ABaC  heterotrimers and then 
the activity (4).  
Methods 
Both SK-N-BE neuroblastoma cell line and TgCRND8 mice were used. In vitro, we used culture media without folate, B12 and 
B6, whereas in vivo, mice were fed with a diet deficient of the same vitamins. Postmortem human entorhinal cortex of healthy 
control subject and AD patients categorized as stage VI of Braak and Braak were used to study GSK3β gene promoter. The 
methylation status of  GSK3β promoter was analyzed by bisulphite method by standard procedures (5) with modifications 
previously described (6). We analyzed expression levels of kinase and phosphatase with quantitative Real-Time PCR, western blot 
and activity assay. 
Results 
We found that alteration of homocysteine (Hcy) metabolism by B vitamin deficiency causes PP2Aca and GSK3b genes 
overexpression both in neuroblastoma cells and in mice brain. Western blot analysis showed a increase of the Leu309-
demethylated PP2Ac and a decrease of methylated PP2Ac in cells and in mice brain in B vitamin condition. As a consequence of 
lowered PP2AC-terminal Leu309 methylation, we found a decrease of PP2A activity and exogenous S-adenosylmethionine (SAM) 
was able to restore the activity of major tau phospatase. Although we observed a decrease of inactive form of GSK3β (p-GSK3β 
Ser9) levels both in cells and in mice brain, no modulation on GSK3b activity was observed. Tau phosphorylation at Ser396 and at 
Ser202/Thr205, increased in B vitamin deficiency, was reverted to control like value by SAM supplementation. The analysis of a 
putative CpG islands in human GSK3β  promoter in postmortem AD brain showed a general hypomethylation of this region 
without differences between control subject and AD patients as well as GSK3β mRNA expression. Instead, a prominent increase of 
inactive form of GSK3β in AD patients was found. 
Conclusions 
The aim of this work was to investigate if DNA or protein methylation could affect equilibrium between the major kinase 
and phosphates involved in tau hyperphosphorylation (GSK3β and PP2A). While both genes were up-regulated by inhibiting 
methylation reactions, only PP2A activity was influenced by Hcy metabolism alteration (7). PP2A activity decreased as a 
consequence of lowered PP2AC-terminal Leu309 methylation and exogenous SAM was able to restore the activity of major 
tau phospatase (8). Therefore, we suppose that tau hyperphosphorylation appears to result from a decreased PP2A activity 
towards tau rather than increased kinase activity. 
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Introduction 
Recent hypotheses stress a central role of one-carbon metabolism both in amyloidogenesis and tau alterations, the two 
major hallmarks of Alzheimer’s Disease (AD), due to changes in methylation and oxidation reactions. Previous data 
obtained in our laboratory, using a nutritional B-vitamin deficiency model, already showed that two genes involved in 
amyloid production (PSEN1 and BACE1) were modulated by one-carbon metabolism alterations. In particular, PSEN1 
was modulated by DNA methylation whereas the mechanisms responsible for BACE1 modulation are probably dealing 
with oxidation. Consequently to modulation of these two genes, production of amyloid peptides was increased. We also 
demonstrated that S-adenosylmethionine (SAM) supplementation was able to contrast the AD-like features induced by 
B vitamin deficiency. Here we studied the effect a combination of SAM and SOD (Superoxide-dismutase), in the same 
model. 
 
Methods 
TgCRND8 mice (carrying a double Indiana/Swedish mutated APP transgene) were grown either with control or vitamin 
B deficient diet, with or without oral supplementation of SAM + SOD (SAM 200 µg + SOD 2.5 per day) or SAM (400 
µg)  and SOD (5 U) alone. We measured: i) methylation metabolites by HPLC; ii) oxidative stress by lipid peroxidation 
assay; iii) PSEN1 and BACE expression by Real-Time PCR and western blotting; iv) amyloid deposition by ELISA 
tests and immunohistochemistry. 
 
Results 
SAM and SOD were able to revert (or prevent) the observed exacerbation of Alzheimer-like features induced by B 
vitamin deficiency in TgCRND8 mice: SAM/SAH ratio decrease, lipid peroxidation, PSEN1 and BACE over-
expression, increase in amyloid processing and deposition. SAM and SOD combination shows a synergic effect versus 
the use of the two single molecules. 
 
Conclusions 
These findings evidence the beneficial effects of the combined administration of SAM and SOD in AD transgenic mice. 
Interestingly, SAM + SOD were able to contrast also the amyloid deposition normally observed in these mice (without 
the induction exerted by B vitamin deficiency). Although the precise mechanism of action of SOD remains to be 
elucidated, these preclinical data stress the importance of a clinical trial with SAM + SOD in order to evaluate its 
efficacy in AD treatment or prevention, alone or as co-adjuvant of current therapies. 
 
Disclosure: This work was partially granted by Gnosis s.p.a. A. Fuso and S. Scarpa are co-owner of a patent on the use 
of SOD and SAM in AD. 
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Introduction 
During lifetime a number of proteins escape the intracellular proteostatic control and 
accumulate. Accumulated, not in time degraded proteins tend to aggregate and built up various 
forms of intracellular protein aggregates [1,2]. Noteworthy such protein accumulation is a long 
lasting process and, therefore, the amount of aggregated proteins increase with aging [2,3]. 
Under certain, often unknown, conditions protein aggregation is enhanced, so that often in a 
defined set of cells protein aggregates accumulate in a relatively early stage of life. Such an 
early protein aggregation is accompanying several diseases [3]. Whether the protein 
accumulation/aggregation is the cause for the disease or just accompanying the 
pathophysiology, is the subject of intensive investigation. However, there are a number of 
reasons for such metabolic changes leading to protein aggregation, including genetic ones as in 
Huntington disease or the familiar form of Amyotrophic Lateral Sclerosis, or more likely 
environmental or metabolic ones as in Alzheimers or Parkinsons disease [4]. 
However, it is widely accepted that the reduction of protein aggregation or growth rate will 
have a positive effect on the outcome of the patients or slow down the progression of these 
diseases.  
 
Intracellular proteostatic control 
There are several major intracellular protein homeostasis systems. This includes in general the 
protein chaperoning system to ensure the normal protein folding during protein synthesis and 
to prevent the aggregation of proteins in an unfolded state and of course the intracellular 
proteolytic systems [4,5,6]. In general there are two major proteolytic systems in a mammalian 
cell: the proteasomal system and the lysosomal-autophagic system. However, in mitochondria 
for example additional systems exist [4,7]. The proteasomal and the autophagic system seem to 
be connected via a targeting system, which includes at least the ubiquitination system. The 
proteasomal system in general is responsible for the degradation of short lived, regulatory 
proteins [4,7], while the autophagy is responsible for the degradation of long-lived proteins and 
cellular organelles. Interestingly, there is convincing evidence that the proteasomal system is 
also responsible for the degradation of oxidatively damaged proteins [8,9,10]. However, once 
oxidized proteins are aggregated the proteasome is unable to degrade them [1, 11]; in fact the 
activity of the proteasomal system is rather negatively influenced by the presence of protein 
aggregates [11, 12].  
Importantly, the autophagic-lysosomal system is able to deal with aggregated proteins and take 
them up into the autophagosome via a process called macroautophagy or in this case 
aggrephagy [13,14]. These protein aggregates are then transferred into lysosomes, where 
proteolytic enzymes (the cathepsins) are present [15]. 
 
Oxidized cross-linked protein aggregates 
As pointed out above, proteins might accumulate and aggregate due to metabolic processes or 
in the pathophysiology of the diseases. It is assumed that the aggregation of proteins takes 
place at least at the beginning or to a certain extend due to non-covalent interactions. It is 
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thinkable, that such a process takes place due to insufficient degradation of malfolded newly 
synthesised proteins. The major driving force for the accumulation of such proteins is perhaps 
surface hydrophobicity [1, 16]. Such unfolded proteins accumulate in structures referred to as 
aggresomes [17] and are afterwards via aggrephagy transferred into lysosomes and degraded. 
However, if such aggresomes stay in an intracellular environment for a long time, it is likely 
that proteins become covalently cross-linked due to the interaction with carbohydrate- or lipid-
driven metabolic cross-linkers. The same is true for oxidatively damaged proteins. Such 
proteins are bearing highly reactive surface motives, including carbohydrates or 
hydroperoxides, which are able to cross link with other proteins [1,18]. With other words such 
protein aggregates tend to attract new proteins and grow with time [1,18]. For such covalently 
cross-linked proteins the degradation is in mammalian cells impossible. The proteasomal 
system is for sure not able to degrade protein aggregates [1,10], moreover it is inhibited by 
formed aggregates [11,12]. One way to avoid the dramatic inhibition of the proteasome by 
protein aggregates is the uptake in the autosomal-lysosomal compartment. However, cross-
linked proteins are also not completely degraded within lysosomes, but accumulate there and 
form lipofuscin [19,20]. So, more that 90% of the intracellular lipofuscin is accumulated in the 
lysosomal compartment [20]. 
 
Possible strategies to reduce protein aggregates 
Obviously, two possible strategies for the reduction of the protein aggregate amount exist: the 
reduced formation or the dissolving of the protein aggregates. Both processes are theoretically 
possible, but are in practice problematic. The prevention of protein aggregate formation might 
be achieved via a modulation of the metabolism, which is difficult since in aging and several 
diseases the protein aggregation takes years or even decades. A permanent stimulation of 
proteostatic control systems might be favourable. Positive results were achieved in genetically 
modified experimental models [21]. Since such an approach for humans is rather impossible, 
the dissolving of protein aggregates is perhaps the way to go. One way here would be the 
‘breaking’ of the covalent cross-links of protein aggregates. This might result in soluble break-
down products, which can be either excluded from the intracellular environment or be degraded 
by intracellular proteolytic systems. Another way to reduce the protein aggregation rate is to 
prevent in a rather advanced stage of aggregate formation the growing of the aggregate. It is 
thinkable, that due to pharmacological intervention the reactive surface motives of protein 
aggregates become neutralized and the rate of aggregate growths is slowed down. 
 
It is unclear today which way of prevention or slowing down the dramatic protein aggregation 
in aging and several diseases will be successful. However, achieving such a goal will be of 
utmost importance for the prevention and treatment of several diseases. 
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